Evaluating the Benefit of Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the benefit of the investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.

Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.

During the discussion, Radin addresses what the benefit or added benefit of the 2 mg dose may be for patients, and why it was important to assess this dose that in addition to the previously FDA approved .5 mg and 1 mg doses.